PPARγ agonist-23
PPARγ agonist-23 (Compound 9) is an orally active PPARγ agonist with an EC50 of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis.
For research use only. We do not sell to patients.
- Formula: C28H18D7NO7S
- Molecular Weight:526.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
PPARγ 0.32 μM (EC50) |
In Vitro
Parmacokinetics
| Species | Dose | Route | Cmax | AUC0-24 | Tmax | T1/2 |
|---|---|---|---|---|---|---|
| Rat[1] | 15 mg/kg | p.o. | 1693 ± 339 ng/mL | 8711 ± 871 ng·h/mL | 1.60 ± 0.13 h | 2.25 ± 0.45 h |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male; NASH induced via high-fat diet and streptozotocin)[1]
-
Dosage:25 mg/kg
-
Administration:p.o.; daily
-
Result:Significantly reduced liver triglyceride levels.
Reduced steatosis scores by 36.8% (P < 0.05) and ballooning scores by 49% (P < 0.05).
Produced a statistically significant improvement in the overall Non-alcoholic Fatty Liver Disease Activity Score (NAS) (P < 0.05).
Showed no significant difference in weight gain compared to vehicle group.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Molecular Weight 526.61
-
Formula C28H18D7NO7S
-
SMILES
[2H]C([2H])([2H])OC1=CC(OC([2H])([2H])[2H])=CC(/C=C(C(OC)=O)\C2=CC=C(OC3=CC=C(C[C@@]4([2H])C(NC(S4)=O)=O)C=C3)C=C2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Liver Histomorphometry
Liver histomorphometry is a quantitative histological approach used to measure structural alterations in hepatic tissue, including parenchymal loss, steatosis, fibrosis, and vascular remodeling, by combining stained tissue section analysis with stereological or computerized image-based measurements. Classical morphometric frameworks quantify volume fractions of liver compartments and fibrotic regions using systematic sampling and image analysis, enabling objective comparison of pathological changes across experimental groups. These approaches are widely applied in liver cirrhosis and fibrosis studies to reduce subjectivity in histological scoring and improve reproducibility of tissue evaluation. Recent methodological advances integrate automated image analysis and radiomics-based extraction of histological features from standard liver stains (e. g. , H&E and fibrotic stains), enabling quantitative correlation between morphometric features and fibrosis stages in non-alcoholic fatty live
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PPARγ agonist-23 Related Classifications
HY-181896S Related Classifications
Powered by Bioz